Related Experiment Video
Updated: Apr 15, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Designer Podophyllotoxin Derivatives with Significantly Improved Safety by Targeting LAT1 for the Treatment of
Manwei Jia1, Xiangqian Gao2, Jianbin Han2
1School of Pharmaceutical Science and Technology, Institute of Molecular Plus, State Key Laboratory of Synthetic Biology, MOE Key Laboratory of Systems Bioengineering, Frontiers Science Center for Synthetic Biology (Ministry of Education of China), Haihe Laboratory of Sustainable Chemical Transformations, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, P. R. China.
Abstract:
The severe toxicity of podophyllotoxin and its analogs primarily constrains their clinical application. We designed and synthesized a series of novel podophyllotoxin derivatives that target tumor-specific transporters to enhance tumor selectivity and reduce systemic toxicity. Among the new analogs, B11 as a LAT1-targeted amino acid conjugate, exhibited significantly greater anticancer activity against Eca109 cells than etoposide and with an ideal druggability profile. B11 achieved a 64.6% TGI versus 30.6% for etoposide in mice bearing Eca109 xenografts in a single drug treatment. The MTD studies showed a more than 4-fold improvement for B11 in animal tolerability compared to etoposide. Pharmacokinetic experiments revealed that B11 can achieve a higher drug distribution in tumors and minimize drug concentration in vital organs. Mechanistic studies indicated that B11 could accumulate in tumor cells in a LAT1-dependent manner and exert its antitumor effects by cytoskeleton disruption.
Insights
Novel anticancer drug B11, a LAT1-targeted amino acid conjugate, shows superior efficacy and reduced toxicity compared to etoposide. It selectively targets cancer cells, improving tumor distribution and tolerability for potential clinical use.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Podophyllotoxin analogs face clinical limitations due to severe toxicity.
- Targeting tumor-specific transporters offers a strategy to enhance selectivity and reduce systemic side effects.
Purpose of the Study:
- To design and synthesize novel podophyllotoxin derivatives with improved tumor selectivity.
- To evaluate the anticancer activity, druggability, and safety profile of a LAT1-targeted amino acid conjugate, B11.
Main Methods:
- Synthesis of novel podophyllotoxin derivatives.
- In vitro anticancer activity assays against Eca109 cells.
- In vivo efficacy studies using Eca109 xenografts in mice.
- Maximum Tolerated Dose (MTD) studies.
- Pharmacokinetic analyses and mechanistic investigations.
Main Results:
- B11 demonstrated significantly greater anticancer activity against Eca109 cells than etoposide.
- B11 achieved a 64.6% tumor growth inhibition (TGI) versus 30.6% for etoposide in vivo.
- B11 exhibited over a 4-fold improvement in animal tolerability compared to etoposide.
- Pharmacokinetics showed enhanced tumor drug distribution and reduced concentration in vital organs.
- B11 accumulation in tumor cells was LAT1-dependent, leading to cytoskeleton disruption.
Conclusions:
- B11, a LAT1-targeted amino acid conjugate, represents a promising anticancer agent with enhanced efficacy and reduced systemic toxicity.
- Its selective tumor targeting and favorable druggability profile warrant further clinical investigation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...